Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing proces…
$10.61-0.66%
报价 2026-11-06
市值
$726.5M
EV
$1.18B
PE (TTM)
17.3x
预期 PE (FY2026)
13.8x
52 周区间距高点 -30.5%
$6.53$15.26
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-07未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.1x | 0.78 → 0.89（1.1x） | 12.0 |
| FY+32028-12 | 1.2x | 0.78 → 1.03（1.3x） | 10.3 |
毛利率 68% · TTM 收入 $586M · 基数 EPS 0.78（调整后）
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| BVSBioventus Inc. | $726.5M | -0.7% | +5.6% | 69% | 17.3x | 12.7x | 10.0x | |
| BFLYButterfly Network, Inc. | $1.7B | +4.9% | +36.1% | 73% | – | – | – | 高增长 |
| CBLLCeriBell, Inc. | $1.03B | +2.2% | +29.3% | 88.9% | – | – | – | |
| KIDSOrthoPediatrics Corp. | $829.3M | -1.4% | +12.9% | 73.8% | – | 364.7x | 253.5x | GARP |
| VREXVarex Imaging Corporation | $783M | -0.4% | +3.8% | 34.3% | 35.2x | 12.1x | – | |
| CTKBCytek Biosciences, Inc. | $757.8M | +8.0% | +6.0% | 53.2% | – | – | – | |
| TMCITreace Medical Concepts, Inc. | $262.1M | -3.6% | -2.7% | 79.5% | – | – | – | |
| LABStandard BioTools Inc. | $251M | +2.2% | +2.7% | 48.3% | – | – | – | |
| 同行中位数 | – | – | +6.0% | 73% | 35.2x | 188.4x | 253.5x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-06-27 Q2 2026 | 2026-03-28 Q1 2026 | 2025-12-31 Q4 2025 | 2025-09-27 Q3 2025 | 2025-06-28 Q2 2025 | 2025-03-29 Q1 2025 | 2024-12-31 Q4 2024 | 2024-09-28 Q3 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $153.2M | $132.1M | $157.9M | $138.7M | $147.7M | $123.9M | $153.6M | $139M |
| Gross Margin | 69% | 67.9% | 68.1% | 67% | 68.2% | 65.8% | 66.8% | 67.3% |
| Operating Margin | 12.5% | 6.7% | 13.8% | 8.7% | 12.6% | 4% | 5.2% | 2.9% |
| Net Income | $33.4M | $3.1M | $14.8M | $3.2M | $7.5M | $-2.6M | $-156,000 | $-4.8M |
| Diluted EPS | 0.47 | 0.04 | 0.21 | 0.05 | 0.11 | -0.04 | -0 | -0.07 |
| Operating Cash Flow | $19.9M | $8.9M | $38M | $30.1M | $25.9M | $-19.3M | $19.3M | $10.3M |
研究材料
电话会纪要摘要
暂无纪要摘要。